在65岁及以上成人中评估BNT162b2新冠疫苗加强针(第三剂)与20价肺炎球菌结合疫苗联合接种的安全性、耐受性和免疫原性的随机试验
这项3期随机双盲多中心研究纳入570名65岁及以上成人,按1:1:1随机分为PCV20与BNT162b2联合接种组、单独接种PCV20组或单独接种BNT162b2组。结果显示联合接种耐受性良好,局部反应和全身事件多为轻至中度,不良事件和严重不良事件发生率低且组间相似,无不良事件导致中止接种,无严重不良事件被认为与接种相关;联合接种组与单独接种组的免疫应答相似。结论认为两种疫苗的安全性及免疫原性相似,提示这两种疫苗可以联合接种。
要点
- 联合接种PCV20与BNT162b2加强针耐受性良好,局部反应和全身事件多为轻至中度。
- 不良事件和严重不良事件发生率低且组间相似,无不良事件导致中止,无严重不良事件被认为与接种相关。
- 联合接种组与单独接种组的免疫应答相似,提示两种疫苗可以联合接种。
核心结论
- PCV20与BNT162b2联合接种的安全性和免疫原性与单独接种PCV20或BNT162b2相似,提示这两种疫苗可以联合接种。
研究设计与样本
- 3期随机双盲多中心研究,纳入570名65岁及以上成人,按1:1:1随机分为PCV20与BNT162b2联合接种组、单独接种PCV20组或单独接种BNT162b2组(以生理盐水盲法)。
主要发现
- 联合接种PCV20与BNT162b2耐受性良好,局部反应和全身事件多为轻至中度,注射部位疼痛和乏力分别为最常见的局部和全身事件。
- 不良事件和严重不良事件发生率低且组间相似,无不良事件导致中止接种,无严重不良事件被认为与接种相关。
- 联合接种组和单独接种PCV20组的调理吞噬活性几何平均增长倍数(GMFR,基线至1个月)分别为2.5-24.5和2.3-30.6(跨PCV20血清型)。
- 联合接种组和单独接种BNT162b2组的全长S结合IgG的GMFR分别为35.5和39.0,针对SARS-CoV-2野生型病毒的中和滴度GMFR分别为58.8和65.4。
临床怎么用
- 原文结论提示PCV20与BNT162b2加强针可以联合接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older adults are at increased risk of adverse outcomes from pneumococcal disease and COVID-19. Vaccination is an established strategy for preventing both illnesses. This study evaluated the safety and immunogenicity of coadministration of the 20-valent pneumococcal conjugate vaccine (PCV20) and a booster (third dose) of BNT162b2 COVID-19 vaccine. METHODS: This phase 3, randomized, double-blind, multicentre study included 570 participants aged ≥65 years randomized 1:1:1 to PCV20 and BNT162b2 coadministered, or PCV20 or BNT162b2 only (administered with saline for blinding). Primary safety endpoints included local reactions, systemic events, adverse events (AEs) and serious AEs (SAEs). Secondary objectives were immunogenicity of PCV20 and BNT162b2 when administered together or separately. RESULTS: Coadministration of PCV20 and BNT162b2 was well tolerated. Local reactions and systemic events were generally mild-moderate; injection-site pain and fatigue were the most frequent local and systemic events, respectively. AE and SAE rates were low and similar across groups. No AEs led to discontinuation; no SAEs were considered vaccination-related. Robust immune responses were observed, with opsonophagocytic activity geometric mean fold rises (GMFRs; from baseline to 1 month) of 2.5-24.5 and 2.3-30.6 across PCV20 serotypes in Coadministration and PCV20-only groups, respectively. GMFRs for full-length S-binding IgG of 35.5 and 39.0, and for neutralizing titres against SARS-CoV-2-wild type virus of 58.8 and 65.4, were observed in the Coadministration and BNT162b2-only groups, respectively. CONCLUSIONS: Safety and immunogenicity of coadministered PCV20 and BNT162b2 were similar to those of PCV20 or BNT162b2 administered alone, suggesting that the 2 vaccines may be coadministered. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04887948.
引用
- Fitz-Patrick D, Young M, Yacisin K, et al. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old. Vaccine. 2023. PMID: 37244809. doi:10.1016/j.vaccine.2023.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。